GlobeNewswire
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
📈
AI Sentiment
Highly Positive
9/10
- Home
- MAIA
as of 03-06-2026 3:44pm EST
$1.53
$0.01
-0.33%
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 49.3M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | 29.53 |
| 52 Week Low/High: | $0.87 - $3.19 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.42 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered MAIA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 70.32%
70.32%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
Louie Ngar Yee
Buy
Director
MAIA Dec 22, 2025
Avg Cost/Share
$1.22
Shares
81,699
Total Value
$99,999.58
Owned After
1,248,888
SEC Form 4
CHAOUKI STEVEN M
Buy
Director
MAIA Dec 22, 2025
Avg Cost/Share
$1.22
Shares
40,849
Total Value
$49,999.18
Owned After
151,873
SEC Form 4
Smith Stan
Buy
Director
MAIA Dec 22, 2025
Avg Cost/Share
$1.22
Shares
57,189
Total Value
$69,999.34
Owned After
1,421,478
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Louie Ngar Yee | MAIA | Director | Dec 22, 2025 | Buy | $1.22 | 81,699 | $99,999.58 | 1,248,888 | |
| CHAOUKI STEVEN M | MAIA | Director | Dec 22, 2025 | Buy | $1.22 | 40,849 | $49,999.18 | 151,873 | |
| Smith Stan | MAIA | Director | Dec 22, 2025 | Buy | $1.22 | 57,189 | $69,999.34 | 1,421,478 |
Earnings Transcripts
SEC 8-K filings with transcript text
2023 Q3 Q3 2023 Earnings
8-K SELL Nov 7, 2023 · 100% conf.
2023
Q3
Q3 2023 Earnings
8-K SELLNov 7, 2023 · 100% conf.
AI Prediction SELL
1D
-4.13%
$2.07
5D
-8.20%
$1.98
20D
-29.89%
$1.51
Price: $2.16 Prob +5D: 0% AUC: 1.000
0001193125-23-271933
8-K
false 0001878313 0001878313 2023-11-07 2023-11-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023
MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-41455
83-1495913
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
444 West Lake Street, Suite 1700
Chicago, IL
60606
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (312) 416-8592
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
MAIA
NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 7, 2023, MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended September 30, 2023, attached hereto as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. As disclosed in Item 2.02 above, on November 7, 2023, the Company issued a press release announcing its results of operations for the quarter ended September 30, 2023, attached hereto as Exhibit 99.1. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events
2023 Q2 Q2 2023 Earnings
8-K Aug 8, 2023
2023
Q2
Q2 2023 Earnings
8-KAug 8, 2023
0001193125-23-205615
8-K
false 0001878313 0001878313 2023-08-08 2023-08-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2023 Date of Report (Date of earliest event reported)
MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-41455
83-1495913
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
444 West Lake Street, Suite 1700
Chicago, IL
60606
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (312) 416-8592 N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
MAIA
NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On August 8, 2023, MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2023, attached hereto as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. Press Release As disclosed in Item 2.02 above, on August 8, 2023, the Company issued a press release announcing its results of operations for the quarter ended June 30, 2023, attached hereto as Exhibit 99.1. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking st
2023 Q1 Q1 2023 Earnings
8-K May 8, 2023
2023
Q1
Q1 2023 Earnings
8-KMay 8, 2023
0001564590-23-007055
maia-8k_20230508.htm
false 0001878313
0001878313
2023-05-08 2023-05-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
May 8, 2023
Date of Report (Date of earliest event reported)
MAIA Biotechnology, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-41455
83-1495913
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
444 West Lake Street, Suite 1700
Chicago, IL
60606
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (312) 416-8592
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
MAIA
NYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 8, 2023, MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended March 31, 2023, attached hereto as Exhibit 99.1.
Item 7.01. Regulation FD Disclosure.
Press Release
As disclosed in Item 2.02 above, on May 8, 2023, the Company issued a press release announcing its results of operations for the quarter ended March 31, 2023, attached hereto as Exhibit 99.1.
The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncerta
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
GlobeNewswire
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
📊
AI Sentiment
Positive
7/10
MT Newswires
MAIA Shares Fall After Pricing of $30 Million Public Offering
📉
AI Sentiment
Negative
2/10
GlobeNewswire
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
➖
AI Sentiment
Neutral
4/10
GlobeNewswire
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
➖
AI Sentiment
Neutral
4/10
Compare MAIA vs Leading Stocks
See how MAIA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.